Completed PHASE2 INTERVENTIONAL 3-arm NCT00640185

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety, Tolerability and Efficacy of 40 mg QD and 80 mg QD ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Attention-Deficit/Hyperactivity Disorder

Interventions ABT-089 Placebo

Updated 7 times since 2017 Last updated: Jan 10, 2013 Started: Mar 31, 2008 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Attention-Deficit/Hyperactivity Disorder and is currently completed. AbbVie (prior sponsor, Abbott) leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie (prior sponsor, Abbott)

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bellevue, United States , Eugene, United States , Farmington Hills, United States , Jacksonville, United States , Lafayette, United States , Memphis, United States , Orlando, United States , Overland Park, United States , Portland, United States , Seattle, United States and 2 more locations